| Quarterly Financials | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 100 | 184 | 138 | 148 | 146 | 162 | 235 | 241 | 226 | 239 | 198 | 173 | 219 | 253 | 217 | 247 | 214 | 223 | 153 | 139 | 137 | 154 | 168 | 138 | 176 | 201 | 222 | 179 | 196 | 175 | 211 | 188 | 165 | 225 | 206 | 204 | 188 | 223 | 226 | 210 | 243 | 265 |
| Expenses | 60 | 132 | 104 | 95 | 101 | 126 | 187 | 182 | 161 | 179 | 148 | 164 | 165 | 187 | 177 | 212 | 163 | 185 | 115 | 117 | 110 | 120 | 126 | 115 | 134 | 167 | 256 | 147 | 150 | 148 | 158 | 179 | 135 | 158 | 157 | 199 | 149 | 176 | 181 | 177 | 166 | 213 |
| EBITDA | 40 | 51 | 34 | 52 | 46 | 36 | 48 | 60 | 65 | 61 | 50 | 9 | 55 | 66 | 40 | 35 | 51 | 38 | 39 | 21 | 27 | 35 | 42 | 23 | 42 | 35 | -33 | 32 | 46 | 27 | 53 | 9 | 29 | 67 | 49 | 5 | 39 | 47 | 45 | 33 | 77 | 52 |
| Operating Profit % | 36 % | 25 % | 21 % | 34 % | 27 % | 21 % | 18 % | 27 % | 28 % | 20 % | 25 % | 2 % | 20 % | 18 % | 20 % | 13 % | 23 % | 12 % | 22 % | 2 % | 15 % | 21 % | 23 % | 13 % | 21 % | 15 % | -18 % | 12 % | 21 % | 14 % | 23 % | 3 % | 15 % | 26 % | 22 % | -0 % | 19 % | 19 % | 14 % | 11 % | 20 % | 13 % |
| Depreciation | 3 | 6 | 3 | 2 | 4 | 4 | 11 | 1 | 5 | 5 | 7 | 5 | 2 | 2 | 2 | 2 | 3 | 4 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 6 | 6 | 7 | 7 | 7 | 7 | 8 | 8 | 8 | 8 |
| Interest | 5 | 5 | 2 | 7 | 4 | 4 | 4 | 8 | 7 | 6 | 5 | 5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 2 | 0 | 1 | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 5 | 2 | 2 | 2 | 2 | 2 | 4 | 1 | 2 | 6 | 3 |
| Profit Before Tax | 33 | 41 | 31 | 43 | 41 | 36 | 38 | 60 | 56 | 52 | 39 | -1 | 51 | 63 | 37 | 32 | 47 | 34 | 34 | 13 | 20 | 30 | 37 | 17 | 37 | 30 | -39 | 27 | 39 | 20 | 47 | -1 | 22 | 59 | 40 | -4 | 30 | 36 | 36 | 23 | 63 | 41 |
| Tax | 13 | 13 | 7 | 15 | 13 | 15 | 17 | 18 | 19 | 12 | 13 | 12 | 12 | 21 | 9 | 13 | 14 | 3 | 9 | 8 | 4 | 8 | 10 | 8 | 11 | 8 | 10 | 3 | 12 | 4 | 18 | -4 | 7 | 16 | 11 | 1 | 8 | 10 | 11 | 7 | 19 | 12 |
| Net Profit | 20 | 28 | 24 | 29 | 28 | 21 | 22 | 43 | 37 | 40 | 26 | -14 | 39 | 42 | 27 | 19 | 33 | 31 | 26 | 6 | 17 | 22 | 28 | 8 | 26 | 22 | -49 | 24 | 28 | 16 | 30 | 4 | 14 | 43 | 29 | -5 | 22 | 26 | 26 | 17 | 44 | 29 |
| EPS in ₹ | 1.89 | 2.23 | 2.15 | 1.71 | 2.67 | 2.46 | 2.02 | 3.21 | 2.05 | 4.93 | 1.74 | -1.39 | 3.72 | 4.02 | 2.50 | 1.76 | 3.28 | 3.00 | 2.30 | 0.85 | 1.57 | 1.99 | 2.48 | 0.61 | 2.35 | 2.05 | -4.83 | 1.90 | 2.48 | 1.33 | 2.68 | 0.34 | 1.41 | 4.06 | 2.64 | -0.88 | 1.97 | 2.31 | 2.27 | 1.47 | 4.08 | 2.58 |
Bliss GVS Pharma
Bliss GVS Pharma
175.92
-3.08
(-1.72%)
Market Cap
₹1,857.88 Cr
PE Ratio
16.41
Volume
14,92,326.00
Day High - Low
₹180.25 - ₹171.70
52W High-Low
₹190.97 - ₹108.12
There are new updates from the company1 day ago
View
Key Fundamentals
Market Cap
1,857.88 Cr
EPS
8.02
PB Ratio
1.67
Book Value
107.04
EBITDA
163.20
Dividend Yield
0.28 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
8.27
Debt to Equity
0.09
Actual
Company News
View All News
Bliss GVS Pharma's board approves appointment of CEO S.N. Kamath as Managing Director for three years, subject to shareholder approval through postal ballot.
Bliss GVS Pharma's ESOP Allotment Committee approved the allotment of 66,380 equity shares of Re. 1/- each to eligible employees who exercised stock options under the company's 2019 Employee Stock Option Plan at Rs. 43/- per share. The allotment increases the company's total issued share capital to 10,57,88,972 equity shares aggregating Rs. 10,57,88,972/-, with the newly issued shares carrying a 6-month lock-in period until June 09, 2026.
Bliss GVS Pharma Incorporates Step-Down Subsidiary Theralife Pharma in KenyaNov 25, 2025
Bliss GVS International PTE Ltd, Singapore, a wholly owned subsidiary of Bliss GVS Pharma Limited, has incorporated a wholly owned subsidiary named Theralife Pharma Ltd in Nairobi, Kenya on November 24, 2025. The new pharmaceutical and healthcare entity has a share capital of 1,000 ordinary shares of KES 100, expanding Bliss GVS Pharma's international presence through its Singapore subsidiary.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,737.00 | #1 4,16,764.48 | 40.16 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 41.99 | |
6,496.50 | 1,72,461.66 | 69.16 | 9,712.00 | 18.67 | 2,191 | 35.10 | 54.95 | |
3,834.30 | 1,29,770.14 | 60.40 | 11,539.40 | 6.99 | 1,911 | 30.46 | 64.03 | |
1,496.30 | 1,20,864.24 | 22.30 | 28,409.50 | 7.12 | 5,291 | 3.71 | 43.36 | |
1,265.80 | 1,05,645.41 | 18.66 | 33,741.20 | 16.73 | 5,725 | -0.38 | 50.22 | |
2,107.00 | 96,238.18 | 22.21 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 58.72 | |
917.80 | 92,352.16 | #1 18.57 | 23,511.00 | 18.55 | 4,615 | 34.60 | 41.66 | |
2,193.30 | 90,530.32 | 51.90 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 47.28 | |
1,211.40 | 70,358.31 | 20.66 | 32,345.60 | 9.43 | 3,484 | 3.81 | 55.09 | |
5,566.00 | 66,549.88 | 27.75 | 13,458.30 | 3.70 | 2,216 | 10.98 | 44.89 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
5.91 %
Net Income Growth
10.66 %
Cash Flow Change
3.01 %
ROE
1.72 %
ROCE
0.94 %
EBITDA Margin (Avg.)
-14.12 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 662 | 762 | 1,023 | 860 | 905 | 1,027 | 1,077 | 1,109 | 1,157 | 1,212 | 1,301 |
| Fixed Assets | 234 | 225 | 305 | 143 | 146 | 242 | 234 | 282 | 379 | 370 | 406 |
| Current Assets | 417 | 471 | 566 | 690 | 694 | 770 | 765 | 777 | 697 | 811 | 827 |
| Capital Work in Progress | 0 | 9 | 4 | 1 | 47 | 0 | 2 | 22 | 3 | 8 | 21 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 8 | 4 | 4 |
| Other Assets | 428 | 527 | 714 | 717 | 712 | 786 | 840 | 803 | 768 | 830 | 870 |
| Total Liabilities | 662 | 762 | 1,023 | 860 | 905 | 1,027 | 1,077 | 1,109 | 1,157 | 1,212 | 1,301 |
| Current Liabilities | 243 | 267 | 437 | 299 | 207 | 231 | 204 | 233 | 193 | 157 | 172 |
| Non Current Liabilities | 68 | 50 | 33 | 13 | 38 | 46 | 45 | 29 | 46 | 51 | 37 |
| Total Equity | 352 | 446 | 553 | 548 | 660 | 750 | 828 | 847 | 917 | 1,003 | 1,092 |
| Reserve & Surplus | 327 | 402 | 476 | 526 | 636 | 725 | 798 | 808 | 874 | 957 | 1,040 |
| Share Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 11 | 11 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -34 | 23 | 30 | -11 | -22 | 0 | -2 | 9 | 3 | -1 | 0 |
| Investing Activities | -30 | -50 | -249 | 48 | -79 | -40 | -45 | -103 | -6 | -83 | -75 |
| Operating Activities | 38 | 113 | 290 | 18 | 40 | 47 | 64 | 136 | 34 | 103 | 106 |
| Financing Activities | -42 | -40 | -10 | -76 | 17 | -6 | -21 | -24 | -25 | -21 | -30 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 33.31 % | 33.24 % | 33.19 % | 33.14 % | 33.14 % | 34.51 % | 34.55 % | 34.46 % | 35.04 % | 35.12 % | 35.06 % | 34.97 % | 34.97 % | 34.90 % | 34.82 % | 35.10 % | 35.29 % | 35.44 % | 35.39 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 16.31 % | 0.00 % | 14.73 % | 13.25 % | 12.13 % | 13.51 % | 13.18 % | 12.65 % | 13.27 % |
| DIIs | 6.72 % | 6.72 % | 6.67 % | 6.66 % | 6.66 % | 6.65 % | 6.64 % | 6.63 % | 6.63 % | 6.62 % | 6.61 % | 6.59 % | 6.59 % | 6.58 % | 6.57 % | 6.55 % | 6.55 % | 6.54 % | 5.98 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 23.45 % | 26.90 % | 27.59 % | 28.26 % | 30.37 % | 30.15 % | 30.57 % | 30.74 % | 30.00 % | 30.10 % | 29.17 % | 30.78 % | 31.71 % | 32.84 % | 34.57 % | 32.93 % | 32.63 % | 32.79 % | 32.85 % |
| Others | 36.52 % | 33.14 % | 32.55 % | 31.95 % | 29.84 % | 28.69 % | 28.24 % | 28.18 % | 28.33 % | 28.15 % | 12.84 % | 27.66 % | 12.00 % | 12.43 % | 11.92 % | 11.91 % | 12.34 % | 12.58 % | 12.51 % |
| No of Share Holders | 28,543 | 39,999 | 42,742 | 41,080 | 45,866 | 46,327 | 45,753 | 44,983 | 43,041 | 42,182 | 43,234 | 40,758 | 45,157 | 44,737 | 52,937 | 49,558 | 49,517 | 46,707 | 44,461 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.6 | 1 | 1 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 |
| Dividend Yield (%) | 0.00 | 0.31 | 0.56 | 0.99 | 0.51 | 0.65 | 0.71 | 0.44 | 0.42 | 0.28 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 14 Sept 2021 |  Dividend | ₹ 0.50 /share | 13 Sept 2021 | 122.40 | 110.50 |
| 21 Jun 2022 | Dividend | ₹ 0.50 /share | 20 Jun 2022 | 80.40 | 72.15 |
| 28 Jun 2022 |  Annual General Meeting | NA | 28 Jun 2022 | 80.40 | 75.10 |
| 13 Jul 2023 | Dividend | ₹ 0.50 /share | 12 Jul 2023 | 82.15 | 82.95 |
| 19 Jul 2023 | Annual General Meeting | NA | 19 Jul 2023 | 83.76 | 101.70 |
| 19 Jul 2024 | Dividend | ₹ 0.50 /share | 18 Jul 2024 | 123.60 | 111.29 |
| 25 Jul 2024 | Annual General Meeting | NA | 25 Jul 2024 | 123.60 | 121.20 |
| 24 Oct 2024 |  Quarterly Result Announcement | NA | 24 Oct 2024 | 127.93 | 126.75 |
| 28 Jan 2025 | Quarterly Result Announcement | NA | 28 Jan 2025 | 173.80 | 150.79 |
| 12 May 2025 | Quarterly Result Announcement | NA | 12 May 2025 | 117.80 | 111.84 |
| 24 Jul 2025 | Dividend | ₹ 0.50 /share | 24 Jul 2025 | 111.84 | 156.90 |
| 29 Jul 2025 | Quarterly Result Announcement | NA | 29 Jul 2025 | 161.90 | 155.11 |
| 31 Jul 2025 | Annual General Meeting | NA | 31 Jul 2025 | 111.84 | 183.17 |
| 06 Nov 2025 | Quarterly Result Announcement | NA | 06 Nov 2025 | 152.04 | 153.85 |
Announcements
Announcement under Regulation 30 (LODR)-Change in Management
1 day ago
1 day agoBoard Meeting Outcome for Outcome Of The Board Meeting Held On Tuesday December 23 20251 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Allotment of ESOP / ESPSDec 09, 2025
Dec 09, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Nov 25, 2025
Nov 25, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 24, 2025
Nov 24, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 10, 2025
Nov 10, 2025Grant Of Options Under Bliss GVS Pharma Limited - Employee Stock Options Plan 2019Nov 06, 2025
Nov 06, 2025Details Of Kmps For Reporting Of Disclosure Of Material Events To Stock ExchangesNov 06, 2025
Nov 06, 2025Announcement under Regulation 30 (LODR)-Change in ManagementNov 06, 2025
Nov 06, 2025Announcement under Regulation 30 (LODR)-Change in ManagementNov 06, 2025
Nov 06, 2025Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Yearly Ended September 30 2025Nov 06, 2025
Nov 06, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On Thursday November 06 2025Nov 06, 2025
Nov 06, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSNov 05, 2025
Nov 05, 2025Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30 2025.Oct 29, 2025
Oct 29, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSOct 10, 2025
Oct 10, 2025Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015Oct 06, 2025
Oct 06, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 06, 2025
Oct 06, 2025Closure of Trading WindowSep 30, 2025
Sep 30, 2025Announcement under Regulation 30 (LODR)-Change in ManagementSep 30, 2025
Sep 30, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On Tuesday September 30 2025Sep 30, 2025
Sep 30, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSSep 15, 2025
Sep 15, 2025Announcement under Regulation 30 (LODR)-Credit RatingSep 03, 2025
Sep 03, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 29, 2025
Aug 29, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 08, 2025
Aug 08, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 01, 2025
Aug 01, 2025Proceedings Of 40Th Annual General Meeting Of Bliss GVS Pharma LimitedJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 31, 2025
Jul 31, 2025Grant Of Options Under Bliss GVS Pharma Limited - Employee Stock Options Plan 2019Jul 29, 2025
Jul 29, 2025Outcome Of Board Meeting Held On Tuesday July 29 2025Jul 29, 2025
Jul 29, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On Tuesday July 29 2025Jul 29, 2025
Jul 29, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJul 28, 2025
Jul 28, 2025Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 2025Jul 22, 2025
Jul 22, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 10, 2025
Jul 10, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 09, 2025
Jul 09, 2025Notice Of The 40Th Annual General Meeting (40Th AGM) Of Bliss GVS Pharma LimitedJul 09, 2025
Jul 09, 2025Reg. 34 (1) Annual Report.Jul 09, 2025
Jul 09, 2025Intimation Of Book Closure In Accordance With Regulation 42 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)Jul 08, 2025
Jul 08, 2025Intimation Of Record Date In Accordance With Regulation 42 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)Jul 08, 2025
Jul 08, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 08, 2025
Jul 08, 2025Communication To Shareholders - Intimation Of Tax Deduction On DividendJul 08, 2025
Jul 08, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 04, 2025
Jul 04, 2025Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 02, 2025
Jul 02, 2025Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Jul 01, 2025
Jul 01, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 30, 2025
Jun 30, 2025Notice To Shareholders W.R.T. Transfer Of Unclaimed Final
Dividend 2017-2018 And Its Corresponding Shares To Investor
Education And Protection Fund (IEPF) AuthorityJun 30, 2025
Jun 30, 2025Closure of Trading WindowJun 30, 2025
Jun 30, 2025Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Jun 26, 2025
Jun 26, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJun 12, 2025
Jun 12, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotJun 12, 2025
Jun 12, 2025Mutual Fund Holdings
| Funding House | Current Holding % | 1M Change | 1M Change % | 3M Change % | Last 6M Trend |
|---|---|---|---|---|---|
 Bandhan BSE Healthcare Index Fund Direct-Growth | 0.08% | -24 | 0.00% | 0.00% |
Technical Indicators
RSI(14)
Neutral 64.33
ATR(14)
Volatile 9.65
STOCH(9,6)
Neutral 59.06
STOCH RSI(14)
Overbought 100.00
MACD(12,26)
Bullish 2.62
ADX(14)
Weak Trend 20.29
UO(9)
Bearish 60.15
ROC(12)
Uptrend And Accelerating 4.54
WillR(14)
Overbought -11.12
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
